Cabaletta Bio, Inc. (CABA) Key Metrics
CABA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $239.1M
- Enterprise value
- $174.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.8 10-yr median 2.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 3.48
CABA key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCABA valuation Price multiples at each fiscal year-end price.
CABA returns How much profit the business earns on the capital it uses.
CABA per-share figures Results divided by the shares outstanding at year-end.
CABA financial health Debt, liquidity and how easily interest is covered.
CABA efficiency & capital use Working capital cycle and where the cash goes.
CABA valuation history
CABA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CABA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CABA cash returned to shareholders
CABA price vs earnings per share
CABA key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $224.0M | $112.3M | $929.5M | — | — | — | — | — | — |
| Enterprise value | $117.5M | −$36.1M | $693.2M | — | — | — | — | — | — |
| Price / book | 2.0 | 0.7 | 3.9 | — | — | — | — | — | — |
| Earnings yield | −75.0% | −103.2% | −7.3% | — | — | — | — | — | — |
| Free cash flow yield | −59.1% | −80.5% | −5.8% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.19 | $2.27 | $22.70 | $9.25 | $3.79 | $12.48 | $13.97 | — | — |
| Per share | |||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$1.64 | −$2.34 | −$1.65 | — | — | — | — | — | — |
| Operating cash flow per share | −$1.28 | −$1.78 | −$1.31 | — | — | — | — | — | — |
| Free cash flow per share | −$1.29 | −$1.83 | −$1.32 | — | — | — | — | — | — |
| Cash per share | $1.31 | $3.31 | $5.89 | — | — | — | — | — | — |
| Book value per share | $1.10 | $3.08 | $5.77 | — | — | — | — | — | — |
| Tangible book value per share | $1.10 | $3.08 | $5.77 | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.04 | $0.02 | — | — | — | — | — | — |
| Debt per share | $0.26 | $0.32 | $0.12 | — | — | — | — | — | — |
| Shares outstanding | 102.3M | 49.5M | 40.9M | — | — | — | — | — | — |
| Change in shares outstanding | +106.7% | +20.8% | — | — | — | — | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −127.0% | −59.6% | −39.7% | −46.6% | −40.0% | −26.2% | −23.7% | — | — |
| Return on assets (ROA) | −95.9% | −52.8% | −36.5% | −42.6% | −37.8% | −25.4% | −17.2% | −71.4% | — |
| Return on tangible assets | −101.7% | −62.6% | −26.7% | −44.3% | −36.0% | −28.3% | −10.7% | −35.7% | — |
| Financial health | |||||||||
| Total debt | $27.1M | $15.6M | $5.0M | $5.1M | — | — | — | $43.9M | — |
| Cash & short-term investments | $133.6M | $164.0M | $241.2M | $106.5M | $122.2M | $108.7M | $136.2M | $33.0M | $1,000 |
| Net debt | −$106.5M | −$148.4M | −$236.2M | −$101.4M | −$122.2M | −$108.7M | −$136.2M | $10.9M | −$1,000 |
| Debt / equity | 0.24 | 0.10 | 0.02 | 0.05 | — | — | — | — | — |
| Debt / assets | 0.16 | 0.08 | 0.02 | 0.04 | — | — | — | 1.29 | — |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | −0.01 |
| Current ratio | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 | 21.92 | 44.66 | 36.05 | 0.00 |
| Quick ratio | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 | 21.92 | 44.66 | 36.05 | 0.00 |
| Interest coverage | -85.9 | -167.3 | — | -46.0 | -63.2 | -68.5 | — | — | — |
| Working capital | $88.7M | $139.6M | $228.5M | $99.3M | $116.2M | $108.4M | $137.4M | $33.1M | −$249,000 |
| Invested capital | $5.5M | $4.0M | −$33,000 | $3.1M | −$4.3M | $882,000 | $2.1M | $214,000 | −$250,000 |
| Tangible asset value | $112.1M | $152.3M | $236.2M | $104.5M | $118.0M | $109.5M | $138.3M | −$10.7M | −$249,000 |
| Net current asset value | $85.8M | $134.0M | $227.0M | $96.4M | $116.2M | $108.4M | $137.4M | −$10.9M | −$249,000 |
| Graham net-net per share | $0.79 | $2.65 | $5.47 | — | — | — | — | — | — |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | — | $10.1M | — | — |
| Share buybacks (net) | $0 | $0 | $0 | $0 | $0 | $192,000 | $1.3M | $169,000 | $0 |
| Capex / revenue | — | — | — | — | — | 6,350,000,000.0% | — | — | — |
| Capex / depreciation | 0.75 | 1.29 | 0.48 | 2.08 | 1.59 | 1.79 | 6.66 | 0.11 | 2.08 |
| Stock-based compensation / revenue | — | — | — | — | — | 43,880,000,000.0% | — | — | — |
| R&D / revenue | — | — | — | — | — | 213,760,000,000.0% | — | — | — |
| SG&A / revenue | — | — | — | — | — | 124,570,000,000.0% | — | — | — |
| Efficiency | |||||||||
| Days payables outstanding | 1,281.6 | 359.1 | 897.1 | 237.6 | 890.3 | 1,115.1 | 2,672.6 | — | — |
| Payables turnover | 0.28 | 1.02 | 0.41 | 1.54 | 0.41 | 0.33 | 0.14 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $5.8M | $4.7M | $3.5M | $2.4M | $1.8M | $1.1M | $761,500 | $396,000 | $189,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CABA's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CABA valuation and financial ratios
Cabaletta Bio earned a return on equity of −127.0% in fiscal 2025. It ended the year with $27.1 million of debt and $133.6 million in cash and short-term investments, a net cash position of $106.5 million.
See the CABA income statement, the CABA chart for price history, or the CABA stock overview for the latest quote and news.
CABA key metrics FAQ
What is Cabaletta Bio's return on equity?
Cabaletta Bio's return on equity (ROE) was −127.0% in fiscal 2025: net income of -$167.9 million on average shareholders' equity of $132.2 million.
How much debt does Cabaletta Bio have?
Cabaletta Bio had total debt of $27.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.24 and more cash than debt.
What is Cabaletta Bio's free cash flow yield?
Cabaletta Bio generated -$132.3 million of free cash flow in fiscal 2025, a free cash flow yield of −59.1% on its market value at year-end ($224.0 million).
What is Cabaletta Bio's current ratio?
Cabaletta Bio's current ratio was 2.77 at the end of fiscal 2025: current assets were 2.77 times current liabilities.